Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 1, 1998, Pages 44-51

  Noda, Yukihiro ^a   Miyamoto, Yoshiaki ^a   Mamiya, Takayoshi ^a   Kamei, Hiroyuki ^a   Furukawa, Hiroshi ^b   Nabeshima, Toshitaka ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MEIJO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DESIPRAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; METHAMPHETAMINE; METIROSINE; NEUROTOXIN; OXIDOPAMINE; OXYGENASE INHIBITOR; PHENCYCLIDINE; RITANSERIN; SEROTONIN 2 ANTAGONIST; SULPIRIDE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVERSION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PREMEDICATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ALPHA-METHYLTYROSINE; ANIMALS; COCAINE; CONDITIONING (PSYCHOLOGY); MALE; MICE; OXIDOPAMINE; PHENCYCLIDINE; RECEPTORS, DOPAMINE D1; RECEPTORS, SEROTONIN; RITANSERIN;

EID: 0031846909     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Acquas E, Carboni E, Leone P and Di Chiara G (1989) SCH 23390 blocks drug-conditioned place-preference and place-aversion: anhedonia (lack of reward) or apathy (lack of motivation) after dopamine-receptor blockade? Psychopharmacology 99:151-155.
2. Barr GA, Paredes W and Bridger WH (1985) Place conditioning with morphine and phencyclidine: Dose dependent effects. Life Sci 36:363-368.
3. Bischoff S, Heinrich M, Sonntag JM and Krauss J (1986) The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptors. Eur J Pharmacol 129:367-370.
4. Bowyer JF, Spuhler KP and Weiner N (1984) Effects of phencyclidine, amphetamine and related compounds on dopamine release from and uptake into striatal synaptosomes. J Pharmacol Exp Ther 229:671-680.
5. Breese GR, Napier TC and Mueller RA (1985) Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: Functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats. J Pharmacol Exp Ther 234:447-455.
6. Bristow LJ, Hutson PH, Thorn L and Tricklebank MD (1993) The glycine/NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents. Br J Pharmacol 108:1156-1163.
7. Cervo L and Samanin R (1995) Effects of dopaminergic and glutamatergic receptor antagonists on the acquisition and expression of cocaine conditioning place preference. Brain Res 673:242-250.
8. Di Chiara G and Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278.
9. Drew KL and Glick SD (1990) Role of D-1 and D-2 receptor stimulation in sensitization to amphetamine-induced circling behavior and in expression and extinction of the Pavlovian conditioned response. Psychopharmacology 101:465-471.
10. Fletcher PJ, Ming ZH and Higgins GA (1993) Conditioned place preference induced by microinjection of 8-OH-DPAT into the dorsal or median raphe nucleus. Psychopharmacology 113:31-36.
11. Goodwin P, Starr BS and Starr MS (1992) Motor responses to dopamine D1 and D2 agonists in the reserpine-treated mouse are affected differentially by the NMDA receptor antagonist MK-801. J Neural Transm 4:15-26.
12. Glowínski J and Iversen LL (1966) Regional studies of catecholamines in the rat brain. I. the disposition of [3H] norepinephrine, [3H] dopamine and [3H]dopa in various regions of the brain. J Neurochem 13:655-669.
13. Hemby SE, Jones GH, Hubert GW, Neill DB and Justice JB Jr (1994) Assessment of the relative contribution of peripheral and central components in cocaine place conditioning. Pharmacol Biochem Behav 47:973-979.
14. Hiroi N and White NM (1991) The amphetamine conditioned place preference: differential involvement of dopamine receptor subtypes and two dopaminergic terminal areas. Brain Res 552:141-152.
15. Hondo H, Yonezawa Y, Nakahara T, Nakamura K, Hirano M, Uchimura H and Tashiro N (1994) Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Res 633:337-342.
16. Isaacs SO, Martin P and Washington JA Jr (1986) Phencyclidine (PCP) abuse. A close-up look at a growing problem. Oral Surg Oral Med Oral Pathol 61:126-129.
17. Kazahaya Y, Akimoto K and Otsuki S (1989) Subchronic methamphetamine treatment enhances methamphetamine-or cocaine-induced dopamine efflux in vivo. Biol Psychiatry 25:903-912.
18. Kitaichi K, Noda Y, Hasegawa T, Furukawa H and Nabeshima T (1996) Acute phencyclidine induces aversion, but repeated phencyclidine induces preference in the place conditioning test in rats. Eur J Pharmacol 318:7-9.
19. 3H] SCH 23390 induced by MK-801 in the mouse striatum. Neuropharmacology 34:341-348.
20. Leone P and Di Chiara G (1987) Blockade D-1 receptors by SCH 23390 antagonizes morphine- and amphetamine-induced place preference conditioning. Eur J Pharmacol 135:251-254.
21. Ljungberg T and Ungerstedt U (1978) Classification of neuroleptic drugs according to their ability it inhibit apomorphine-induced locomotion and gnawing: Evidence for two different mechanisms of action. Psychopharmacology 56:239-247.
22. Maddox VH, Godefroi EF and Parcell RF (1965) The synthesis of phencyclidine and other 1-arylcyclohexylamines. J Med Chem 8:230.
23. Marquis KL and Moreton JE (1987) Animal models of intravenous phencyclidine self-administration. Pharmacol Biochem Behav 27:385-389.
24. Nabeshima T, Kitaichi K and Noda Y (1996) Functional changes in neuronal systems induced by phencyclidine administration. Ann N Y Acad Sci 801:29-38.
25. Nabeshima T, Fukaya H, Yamagucbi K, Ishikawa K, Furukawa H and Kameyama T (1987) Development of tolerance and supersensitivity to phencyclidine in rats after repeated administration of phencyclidine. Eur J Pharmacol 135:23-33.
26. Nabeshima T, Noda Y, Yamaguchi K, Ishikawa K, Furukawa H and Kameyama T (1985) Acute and chronic phencyclidine administration changes serotonin receptors in rat brain. Eur J Pharmacol 109:129-130.
27. Nguyen TV, Kosofsky BE, Birnbaum R, Cohen BM and Hyman SE (1992) Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA 89:4270-4274.
28. Noda Y, Mamiya T, Furukawa H and Nabeshima T (1997) Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Eur J Pharmacol 324:135-140.
29. Noda Y, Yamada K, Komori Y, Sugihara H, Furukawa H and Nabeshima T (1996) Role of nitric oxide in the development of tolerance and sensitization to behavioural effects of phencyclidine in mice. Br J Pharmacol 117:1579-1585.
30. Petersen RC and Stillman RC (1978) Phencyclidine abuse: An appraisal, in National Institute of Drug Abuse Research Monograph, vol 21, pp 1-17, Department of Health, Education and Welfare, Washington, DC.
31. Rao TS, Kim HS, Lehman J, Martin LL and Wood PL (1989) Differential effects of phencyclidine (PCP) and ketamine on mesocortical and mesostiatal dopamine release in vivo. Life Sci 45:1065-1072.
32. Robinson TE, Jurson PA, Bennett JA and Bentgen KM (1988) Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: A microdialysis study in freely moving rats. Brain Res 462:211-222.
33. Schechter MD and Calcagnetti DJ (1993) Trends in place preference conditioning with a cross-indexed bibliography; 1957-1991. Neurosci Biobehav Rev 17:21-41.
34. Shippenberg TS, Bals-Kubik R and Herz A (1993) Examination of the neurochemical substrates mediating the motivational effects of opioids: Role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. J Pharmacol Exp Ther 265:53-59.
35. 3H]serotonin uptake in synaptosomal preparations from rat brain. Biochem Pharmacol 26:1435-1439.
36. Suzuki T, Tsuji M, Mori T, Misawa M and Nagase H (1996) The effects of dopamine D1 and D2 receptor antagonists on the rewarding effects of delta1 and delta 2 opioid receptor agonists in mice. Psychopharmacology 124:211-218.
37. Svensson A, Carlsson A and Carlsson ML (1992) Differential locomotor interactions between dopamineD1/D2 receptor agonists and the NMDA receptor antagonist dizocilpine in monoamine-depleted mice. J Neural Transm 90:199-217.
38. Ujike H, Akiyama K, Nishikawa H, Onoue T and Otsuki S (1991) Lasting increase in D1 dopamine receptors in the lateral part of the substantia nigra pars reticulata after subchronic methamphetamine administration. Brain Res 540:159-163.
39. Yamada S, Kojima H, Yokoo H, Tsutsumi T, Takamuki K, Anraku S, Nishi S and Inanaga K (1988) Enhancement of dopamine release from striatal slices of rats that were subchronically treated with methamphetamine. Biol Psychiatry 24:399-408.